National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Pertuzumab and trastuzumab (Phesgo®). HTA ID: 20053

Pertuzumab and trastuzumab (Phesgo®)  is licensed for the following therapeutic indications:

  • Early breast cancer: is indicated for use in combination with chemotherapy in
    • The neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory or early stage breast cancer at high risk of recurrence
    • The adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence
  • Metastatic breast cancer: is indicated for use in combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

 

NCPE Assessment Process Complete
Rapid review commissioned 07/12/2020
Rapid review completed 06/01/2021
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that pertuzumab and trastuzumab (Phesgo®) not be considered for reimbursement at the submitted price*.

 

* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.